Document is current
Any future updates will be listed below
-
Authors
Ito, Hiromu
Ishikawa, Hajime
Tsuji, Shigeyoshi
Nakayama, Masanori
Nishida, Keiichiro
Mochizuki, Takeshi
Ebina, Kosuke
Kojima, Toshihisa
Matsumoto, Takumi
Kubota, Ayako
Nakajima, Arata
Kaneko, Atsushi
Matsushita, Isao
Hara, Ryota
Sakuraba, Koji
Akasaki, Yukio
Matsubara, Tsukasa
Mochida, Yuichi
Kanbe, Katsuaki
Nakagawa, Natsuko
Murata, Koichi
Momohara, Shigeki
-
Funding
Funding for this research was provided by:
Bristol-Myers Squibb and ONO Pharmaceutical Co.Ltd. (No.IM101-552)
- License Information
-
More Information
Article History
Received: 31 July 2025
Accepted: 28 October 2025
First Online: 21 November 2025
Declarations
:
: This retrospective multicenter cohort study received approval from the Ethics Committee of Kyoto University Graduate School and Faculty of Medicine (No.R0053) and the ethics committees of all participating institutions. Because this is a retrospective cohort study, patient’s written informed consent was waived.
: TM has received speaker fees from AbbVie, Asahi Kasei, Bristol-Myers, Eisai, Eli Lilly, Mochida, and Pfizer. KE also holds the post of the Department of Sports Medical Biomechanics, Osaka University Graduate School of Medicine, which is supported by Asahi-Kasei. KE has received research grants from Asahi-Kasei and Teijin Pharma. KE has received a speaker fee from AbbVie, Amgen, Argenx, Asahi-Kasei, Astellas, Ayumi, Bristol-Myers Squibb, Chugai, Daiichi-Sankyo, Eisai, Eli Lilly, Janssen, Mitsubishi-Tanabe, Ono Pharmaceutical, Pfizer, Sanofi, Taisho, Teijin Pharma, and UCB Japan. RH has received speaker fees from AbbVie G.K., Asahi Kasei Pharma Co., Eisai Co., Ltd and Eli Lilly Japan. TM has received research support from AbbVie GK, Mochida Pharmaceutical Plant Co., Ltd., Nippon Zenyaku Kogyo Co., Ltd.and Gilead Sciences K.K. SM has received consulting/speakers’ fees and/or honoraria from AbbVie GK, Eisai Co., Ltd., Eli Lilly Japan K.K., and Gilead Sciences K.K. The other authors have nothing to disclose.
